Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-729 followed by VTP-300 in virologically suppressed chronic hepatitis B
ACTRN12622000317796Phase 2Completed
- Sponsor
- Arbutus Biopharma Corporation
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Gene Therapies, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing AB-729 lead-in then VTP-300, AB-729 lead-in then placebo and AB-729 lead-in then VTP-300 + nivolumab (3 arms). Started Jun 2022; status: completed.
02
Drugs
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ACTRN12622000317796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000317796.